雌孕激素受体和P-糖蛋白在非小细胞肺癌中的表达及其临床意义

目的 :探讨雌激素受体 (ER)、孕激素受体 (PR)和P -糖蛋白 (P gp)在非小细胞肺癌中的表达与预后的关系。方法 :应用S P免疫组化法检测ER、PR和P gp的表达情况。结果 :ER、PR阳性率分别为 4 5 2 %和 4 0 4 % ;腺癌中均为 6 4 7% ,明显高于其他组织类型 ,P <0 0 1。P gp在肺癌组织阳性表达率为 4 0 4 %。ER、PR和P gp的表达与性别、年龄、组织类型、细胞分化水平和TNM临床分期无关 ,P >0 0 5。P gp阴性患者术后 1、3年无瘤生存期明显高于P gp阳性患者 ,P <0 0 1。肺癌组织中P gp与ER和PR的表达具有明显相关性 ,r =0 32 3,P <0 0 5和r =0 30 8,P <0 0 5。结论 :ER和PR不能作为预测肺癌患者预后的指标。P gp可作为临床判断化疗疗效的参考指标及预测肺癌患者预后的指标。ER和P gp均阳性的肺癌患者 ,辅于性激素治疗 ,疗效更好。

Expression and Clinical Significance of ER,PR and P-gp in NSCLC

Objective To evaluate the relationship between the ER,PR and P-gp with prognosis in NSCLC.Methods The S-P immunohistochemical techniques were used to test the expression levels of ER,PR and P-gp in NSCLC.Results The positive rates of ER and PR were 45.2% and 40.4%.The expression rates of ER and PR were both 64.7% in adenocarcinoma,which were apparently higher than that in other types of lung cancer tissues,P<0.01.The positive rate of P-gp in NSCLC was 40.4%.In lung cancer the expressions of ER,PR and P-gp had no relationship with the patients' sex,age,clinical stage,degree of differentiation of tumor cells,P>0.05.The non-tumor survival rate in the negitive expression of P-gp was higher than that in the positive expression,P<0.01.There were obvious correlation between the expressions of P-gp and ER,PR in lung cancer,P<0.05.Conclusions The expressions of ER and PR could not be taken as the reference indexes to judge the prognosis of patients' conditions.P-gp could be taken as a reference index to judge the clinical effect of the chemotherapy and make prognosis of patients with lung cancer.The expression of P-gp and those of ER and PR in lung cancer tissue were in a positive correlation.